Teva ceo
Mega deal: Teva acquires Emalex for approximately $900 million
The Israeli pharmaceutical giant is accelerating its growth strategy and adding to its portfolio a groundbreaking treatment for Tourette syndrome in children.
Teva share price struggles to recover following $6 billion market loss
US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute
Israel's Teva Pharm to start paying US opioid settlement in 2023, says CEO
Teva's new migraine drug helps contain profit fall
Teva has reduced its spending by $2.5 billion since initiating the restructuring last year.
A tribute to companies whose products have become Israeli icons worldwide
ZIM CEO Eli Glickman pays homage to the CEOs of Teva Israel, Mehadrin, Keter Plastic, and other prominent Israeli companies
Netanyahu thanks United States for 'defending Israel's truth'
Prime Minister Benjamin Netanyahu said that American Vice President Pence is “a great friend of Israel and a great friend of Jerusalem.”
Nation girds for general strike today in protest of Teva layoffs
Morning flights halted at Ben-Gurion, public transit to operate as usual.
Politicians can decry Teva layoffs, but why did they give billions in tax breaks?
Teva has benefited from an estimated NIS 22 billion ($6.2b.) in tax breaks and subsidies from 2006 until today.
Teva Pharmaceuticals to lay off 14,000 employees worldwide, 1,750 in Israel
Teva's shares rallied on Thursday in response to the proposed cutbacks, rising more than 15% in one day on the Tel Aviv stock exchange, as of 4pm Israel time.
Teva Pharmaceuticals considers laying-off 10,000 workers
The Petah Tikva-based company seeks to reduce its expenses by $1.5 billion to $2 billion in the next two years.
Saving Teva
Why the pharmaceutical giant needs to be bailed out
Teva shares plunge again after weak third-quarter
Stock price at lowest level since 2000
Yaron Neudorfer, CEO of Social Finance Israel, pays for success
Social Finance Israel, led by Yaron Neudorfer and his team, has dipped its toe into the water.
